Cargando…

Protein Tyrosine Phosphatase Receptor Type D Regulates Neuropathic Pain After Nerve Injury via the STING-IFN-I Pathway

Neuropathic pain is usually caused by injury or dysfunction of the somatosensory system, and medicine is a common way of treatment. Currently, there are still no satisfactory drugs, like opioids and lidocaine, which carry a high risk of addiction. Protein tyrosine phosphatase receptor type D (PTPRD)...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Chengkuan, Wu, Guangzhi, Zhang, Zhan, Cao, Rangjuan, Cui, Shusen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047945/
https://www.ncbi.nlm.nih.gov/pubmed/35493326
http://dx.doi.org/10.3389/fnmol.2022.859166
_version_ 1784695833026887680
author Sun, Chengkuan
Wu, Guangzhi
Zhang, Zhan
Cao, Rangjuan
Cui, Shusen
author_facet Sun, Chengkuan
Wu, Guangzhi
Zhang, Zhan
Cao, Rangjuan
Cui, Shusen
author_sort Sun, Chengkuan
collection PubMed
description Neuropathic pain is usually caused by injury or dysfunction of the somatosensory system, and medicine is a common way of treatment. Currently, there are still no satisfactory drugs, like opioids and lidocaine, which carry a high risk of addiction. Protein tyrosine phosphatase receptor type D (PTPRD) is a known therapeutic target in addiction pathways and small molecule inhibitors targeting it, such as 7-butoxy illudalic acid analog (7-BIA), have recently been developed to tackle addition. PTPRD is also upregulated in the dorsal root ganglion (DRG) in a rat model of neuropathic pain, but is not yet clear whether PTPRD contributes to the development of neuropathic pain. Here, we established a chronic constriction injury (CCI) and evaluated PTPRD expression and its association with neuropathic pain. PTPRD expression was found to gradually increase after CCI in DRGs, and its expression was concomitant with the progressive development of hypersensitivity as assessed by both mechanical and thermal stimuli. Both PTPRD knockdown and administration of PTPRD inhibitor 7-BIA alleviated CCI-induced neuropathic pain while upregulating STING and IFN-α in the DRG. Treatment with H-151, a STING inhibitor, abolished the analgesic effects of PTPRD knockdown. Taken together, our study suggests that increased levels of PTPRD in the DRG following CCI are involved in the development of neuropathic pain via the STING-IFN-I pathway. 7-BIA, a small molecule inhibitor of PTPRD with anti-addiction effects, may represent a novel and safe therapeutic strategy for the clinical management of neuropathic pain without the risk of addiction.
format Online
Article
Text
id pubmed-9047945
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90479452022-04-29 Protein Tyrosine Phosphatase Receptor Type D Regulates Neuropathic Pain After Nerve Injury via the STING-IFN-I Pathway Sun, Chengkuan Wu, Guangzhi Zhang, Zhan Cao, Rangjuan Cui, Shusen Front Mol Neurosci Neuroscience Neuropathic pain is usually caused by injury or dysfunction of the somatosensory system, and medicine is a common way of treatment. Currently, there are still no satisfactory drugs, like opioids and lidocaine, which carry a high risk of addiction. Protein tyrosine phosphatase receptor type D (PTPRD) is a known therapeutic target in addiction pathways and small molecule inhibitors targeting it, such as 7-butoxy illudalic acid analog (7-BIA), have recently been developed to tackle addition. PTPRD is also upregulated in the dorsal root ganglion (DRG) in a rat model of neuropathic pain, but is not yet clear whether PTPRD contributes to the development of neuropathic pain. Here, we established a chronic constriction injury (CCI) and evaluated PTPRD expression and its association with neuropathic pain. PTPRD expression was found to gradually increase after CCI in DRGs, and its expression was concomitant with the progressive development of hypersensitivity as assessed by both mechanical and thermal stimuli. Both PTPRD knockdown and administration of PTPRD inhibitor 7-BIA alleviated CCI-induced neuropathic pain while upregulating STING and IFN-α in the DRG. Treatment with H-151, a STING inhibitor, abolished the analgesic effects of PTPRD knockdown. Taken together, our study suggests that increased levels of PTPRD in the DRG following CCI are involved in the development of neuropathic pain via the STING-IFN-I pathway. 7-BIA, a small molecule inhibitor of PTPRD with anti-addiction effects, may represent a novel and safe therapeutic strategy for the clinical management of neuropathic pain without the risk of addiction. Frontiers Media S.A. 2022-04-14 /pmc/articles/PMC9047945/ /pubmed/35493326 http://dx.doi.org/10.3389/fnmol.2022.859166 Text en Copyright © 2022 Sun, Wu, Zhang, Cao and Cui. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Sun, Chengkuan
Wu, Guangzhi
Zhang, Zhan
Cao, Rangjuan
Cui, Shusen
Protein Tyrosine Phosphatase Receptor Type D Regulates Neuropathic Pain After Nerve Injury via the STING-IFN-I Pathway
title Protein Tyrosine Phosphatase Receptor Type D Regulates Neuropathic Pain After Nerve Injury via the STING-IFN-I Pathway
title_full Protein Tyrosine Phosphatase Receptor Type D Regulates Neuropathic Pain After Nerve Injury via the STING-IFN-I Pathway
title_fullStr Protein Tyrosine Phosphatase Receptor Type D Regulates Neuropathic Pain After Nerve Injury via the STING-IFN-I Pathway
title_full_unstemmed Protein Tyrosine Phosphatase Receptor Type D Regulates Neuropathic Pain After Nerve Injury via the STING-IFN-I Pathway
title_short Protein Tyrosine Phosphatase Receptor Type D Regulates Neuropathic Pain After Nerve Injury via the STING-IFN-I Pathway
title_sort protein tyrosine phosphatase receptor type d regulates neuropathic pain after nerve injury via the sting-ifn-i pathway
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047945/
https://www.ncbi.nlm.nih.gov/pubmed/35493326
http://dx.doi.org/10.3389/fnmol.2022.859166
work_keys_str_mv AT sunchengkuan proteintyrosinephosphatasereceptortypedregulatesneuropathicpainafternerveinjuryviathestingifnipathway
AT wuguangzhi proteintyrosinephosphatasereceptortypedregulatesneuropathicpainafternerveinjuryviathestingifnipathway
AT zhangzhan proteintyrosinephosphatasereceptortypedregulatesneuropathicpainafternerveinjuryviathestingifnipathway
AT caorangjuan proteintyrosinephosphatasereceptortypedregulatesneuropathicpainafternerveinjuryviathestingifnipathway
AT cuishusen proteintyrosinephosphatasereceptortypedregulatesneuropathicpainafternerveinjuryviathestingifnipathway